CAJ | 학술논문

分析多西他赛联合卡铂方案在三阴性乳腺癌新辅助化疗中的疗效及不良反应。分析2010年03月～2013年09月我院收治的84例TNBC患者临床资料，分析对比多西他赛联合卡铂（TP）方案与吡柔比星、氟尿嘧啶、环磷酰胺（CAF）方案新辅助化疗疗效及不良反应。TP组患者的有效率（RR）优于CAF组，P＜0．05。两组患者的药物不良反应无明显差异，P＞0．05。多西他赛联合卡铂方案用于三阴性乳腺癌新辅助化疗，疗效确切，耐受性良好。
분석다서타새연합잡박방안재삼음성유선암신보조화료중적료효급불량반응。분석2010년03월～2013년09월아원수치적84례TNBC환자림상자료，분석대비다서타새연합잡박（TP）방안여필유비성、불뇨밀정、배린선알（CAF）방안신보조화료료효급불량반응。TP조환자적유효솔（RR）우우CAF조，P＜0．05。량조환자적약물불량반응무명현차이，P＞0．05。다서타새연합잡박방안용우삼음성유선암신보조화료，료효학절，내수성량호。
This article is to analyze the efficacy and adverse reactions of docetaxel and carboplatin as neoadjuvant chemotherapy for triple negative breast cancer (TNBC) .The clinical data of 84 cases of breast cancer was collected from March 2010 to September 2013 in the First Affiliated Hospital of Liaoning Medical College . The article analyzes the efficacy and adverse reactions from that docetaxel and carboplatin ( TP ) regimen compare with pirarubicin , cyclophosphamide ,5-fluorouracil (CAF) in neoadjuvant chemotherapy .TP group of patients with efficient (RR) is superior to CAF group ,P< 0 .05) .Two groups of adverse drug reactions in patients with no significant difference ,P>0 .05 .Combination of docetaxel and carboplatin as neoadjuvant chemotherapy for triple negative breast cancer has definite curative effect and good tolerance .